53
Research Trials
20
Peer-reviewed publications
16
Clinical Conditions
Hyfe pilot study tests a digital therapeutic combining passive cough monitoring with behavioral suppression techniques delivered through the CoughPro app.
This narrative review by Hyfe's R&D team makes the case that continuous cough monitoring (CCM), powered by acoustic AI, transforms cough from a subjective symptom into a quantifiable digital biomarker.
Independent ERS 2025 NeuroCOUGH trial uses the Hyfe Cough Tracker to test feasibility of studying azithromycin's effect on cough and oesophageal motility.
Independent ERS 2025 trial uses the Hyfe Cough Tracker to show azithromycin reduces objective cough frequency by week one in chronic respiratory disease.
This investigator-led open-label trial from the NeuroCOUGH Clinical Research Collaboration used the Hyfe Cough Tracker to characterize, for the first time with continuous objective monitoring, the antitussive effect of long-term azithromycin in chronic respiratory disease. Thirty patients with chronic cough were monitored continuously for one week at baseline and across four weeks of azithromycin 250 mg once daily. Median hourly cough rate fell significantly from 8.9 to 5.5 (p = 0.002), and the novel relief-of-cough metric, the proportion of time not coughing, rose from 74% to 81% (p < 0.001). Improvement was visible by week one and sustained through follow-up, alongside significant gains in cough-specific and disease-specific quality of life measures (LCQ, HARQ, SGRQ). The authors conclude that a randomized controlled trial of azithromycin for chronic cough is justified, and the study illustrates how continuous cough monitoring can surface treatment signals in weeks rather than months.
